Vascular ossification – calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis – calcific uremic arteriolopathy: the emerging role of sodium thiosulfate
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hayden MR, Tyagi SC: Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol. 2004, 3 (1): 1-10.1186/1475-2840-3-1.
Acierno LJ: Atherosclerosis (arteriosclerosis). The History of Cardiology. 1994, New York: Parthenon Publishing Group Inc, 109-126.
Virchow R: Cellular Pathology: As Based Upon Physiological and Pathological Histology. 1971, New York, NY: Dover
Bunting C: The formation of true bone with cellular (red) marrow in a sclerotic aorta. J Exp Med. 1906, 8: 365-376. 10.1084/jem.8.3.365.
Demer LL, Tintut Y: Mineral exploration: search for the mechanism of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award lecture. Arterioscler Thromb Vasc Biol. 2003, 23 (10): 1739-1743. 10.1161/01.ATV.0000093547.63630.0F.
Demer LL, Tintut Y: Osteopontin Between a Rock and a Hard Plaque. Circulation Research. 1999, 84: 250-252.
Giachelli CM: Vascular calcification mechanisms. J Am Soc Nephrol. 2004, 15 (12): 2959-2964. 10.1097/01.ASN.0000145894.57533.C4.
Kizu A, Jono S: [Mechanism of vascular calcification]. Clin Calcium. 2004, 14 (6): 92-96.
Shioi A: [Vascular calcification]. Clin Calcium. 2004, 14 (6): 38-41.
Kondos GT, Hoff JA, Sevrukov A, Daviglus ML, Garside DB, Devries SS, Chomka EV, Liu K: Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003, 107: 2571-2576. 10.1161/01.CIR.0000068341.61180.55.
Jacoby DS, Mohler ER, Rader DJ: Noninvasive atherosclerosis imaging for predicting cardiovascular events and assessing therapeutic interventions. Curr Atheroscler Rep. 2004, 6 (1): 20-26.
Shinnar M, Fallon JT, Wehrli S, Levin M, Dalmacy D, Fayad ZA, Badimon JJ, Harrington M, Harrington E, Fuster V: The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. Arterioscler Thromb Vasc Biol. 1999, 19 (11): 2756-2761.
Tinut Y, Dermer LL: Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidology. 2001, 12: 555-560. 10.1097/00041433-200110000-00012.
Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000, 20 (5): 1262-1275.
Garfinkel A, Tintut Y, Petrasek D, Bostrom K, Demer LL: Pattern formation by vascular mesenchymal cells. Proc Natl Acad Sci U S A. 2004, 101 (25): 9247-9250. 10.1073/pnas.0308436101.
Abedin M, Tintut Y, Demer LL: Mesenchymal stem cells and the artery wall. Circ Res. 2004, 95 (7): 671-676. 10.1161/01.RES.0000143421.27684.12.
Dong C, Goldschmidt-Clermont PJ: Bone sialoprotein and the paradox of angiogenesis versus atherosclerosis. Circulation Research. 2000, 86 (8): 827-828.
Hayden MR, Tyagi SC: Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol. 2002, 1 (1): 3-10.1186/1475-2840-1-3.
Hayden MR, Tyagi SC: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol. 2003, 2 (1): 2-10.1186/1475-2840-2-2.
Cordain L, Eades MR, Eades MD: Hyperinsulinemic diseases of civilization: more than just Syndrome X. Comp Biochem Physiol A Mol Integr Physiol. 2003, 136 (1): 95-112. 10.1016/S1095-6433(03)00011-4.
de Wazieres B, Wendling D, Fest T, Morin G, Dupond JL: [Bone and visceral manifestations of lipoatrophic diabetes. Apropos of a case]. Rev Rhum Mal Osteoartic. 1992, 59 (11): 761-764.
Dacquin R, Davey RA, Laplace C, Levasseur R, Morris HA, Goldring SR, Medhin S, Galson DL, Zajac JD, Karsenty G: Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol. 2004, 164 (4): 509-514. 10.1083/jcb.200312135.
Allison MA, Criqui MH, Wright CM: Patterns and risk factors for systemic calcified atherosclerosis. Arterioscler Thromb Vasc Biol. 2004, 24 (2): 331-336. 10.1161/01.ATV.0000110786.02097.0c.
Mehrotra R, Budoff M, Christenson P, Ipp E, Takasu J, Gupta A, Norris K, Adler S: Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int. 2004, 66 (5): 2022-2031. 10.1111/j.1523-1755.2004.00974.x.
McCullough PA, Sandberg KR, Dumler F, Yanez JE: Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol. 2004, 17 (2): 205-215.
Hayden MR, Tyagi SC: Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction. Case report and systematic scientific review. Cardiovasc Diabetol. 2005, 4 (1): 1-10.1186/1475-2840-4-1.
Aronson D, Rayfield EJ: How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol. 2002, 1 (1): 1-10.1186/1475-2840-1-1.
Shimura E, Okuno S, Kitatani K, Kim M, Shoji T, Nakatani T, Inaba M, Nishizawa Y: Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients – importance of glycaemic control. Diabetologia. 2002, 45 (10): 1446-1448. 10.1007/s00125-002-0920-8.
Niskanen L, Siitonen O, Suhonen M, Uusitupa MI: Medial artery calcification predicts cardiovascular mortality in patients with NIDDM. Diabetes Care. 1994, 17 (11): 1252-1256.
Everhart JE, Pettitt DJ, Knowler WC, Rose FA, Bennett PH: Medial arterial calcification and its association with mortality and complications of diabetes. Diabetologia. 1988, 31 (1): 16-23.
Hayden MR, Tyagi SC: Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond). 2004, 1 (1): 10-10.1186/1743-7075-1-10.
Tseng CH: Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with type 2 diabetes. Diabet Med. 2004, 21 (7): 724-729. 10.1111/j.1464-5491.2004.01239.x.
Hayden MR, Tyagi SC: Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation. Nutr J. 2004, 3 (1): 4-10.1186/1475-2891-3-4.
Li J, Chai S, Tang C, Du J: Homocysteine potentiates calcification of cultured rat aortic smooth muscle cells. Life Sci. 2003, 74 (4): 451-461. 10.1016/j.lfs.2003.06.028.
Moe SM, Chen NX: Inflammation and vascular calcification. Blood Purif. 2005, 23 (1): 64-71. 10.1159/000082013.
Ishimura E, Okuno S, Kitatani K, Maekawa K, Izumotani T, Yamakawa T, Jono S, Shoji T, Shioi A, Inaba M, Massry SG, Nishizawa Y: C-reactive protein is a significant predictor of vascular calcification of both aorta and hand arteries. Semin Nephrol. 2004, 24 (5): 408-412.
Perianayagam MC, Jaber BL, Guo D, King AJ, Pereira BJ, Balakrishnan VS: Defective interleukin-10 synthesis by peripheral blood mononuclear cells among hemodialysis patients. Blood Purif. 2002, 20 (6): 543-550. 10.1159/000066958.
Naidoo DP: The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes. Cardiovasc J S Afr. 2002, 13 (4): 194-199.
Psyrogiannis A, Kyriazopoulou V, Vagenakis AG: Medial arterial calcification is frequently found in patients with microalbuminuria. Angiology. 1999, 50 (12): 971-975.
NKF. K/DoQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification. Am J Kidney Dis. 2002, 39: S1-S266. 10.1053/ajkd.2002.32799.
USRDS. 2004 Annual Data Report: Atlas of End Stage Renal Disease in the United States. Bethesda, MD. 2004
Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998, 32 (5 Suppl 3): S112-S119.
Hayden MR, Tyagi SC: Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit. 2003, 9 (7): SR35-SR52.
Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000, 15 (2): 218-223. 10.1093/ndt/15.2.218.
Moe SM, Chen NX: Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004, 95 (6): 560-567. 10.1161/01.RES.0000141775.67189.98.
Chen NX, Moe SM: Vascular calcification in chronic kidney disease. Semin Nephrol. 2004, 24 (1): 61-68. 10.1053/j.semnephrol.2003.08.014.
McCullough PA, Sandberg KR, Dumler F, Yanez JE: Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol. 2004, 17 (2): 205-215.
Moe SM, O'Neill KD, Resterova M, Fineberg N, Persohn S, Meyer CA: Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant. 2004, 19 (9): 2387-2393. 10.1093/ndt/gfh303.
Scoble JE: Atherosclerotic nephropathy. Kidney Int. 1999, 56 (S71): 106-109. 10.1046/j.1523-1755.1999.07126.x.
Scoble JE, Maher ER, Hamilton G, Dick R, Sweny P, Moorhead JF: Atherosclerotic renovascular disease causing renal impairment – a case for treatment. Clin Nephrol. 1989, 31 (3): 119-122.
Moe SM, Chen NX: Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis. Pediatr Nephrol. 2003, 18 (10): 969-075. 10.1007/s00467-003-1276-0.
Llach F: The evolving pattern of calciphylaxis: therapeutic considerations. Nephrol Dial Transplant. 2001, 16 (3): 448-451. 10.1093/ndt/16.3.448.
Edsall LC, English JC, Patterson JW: Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol. 2004, 31 (3): 247-253. 10.1111/j.0303-6987.2004.00169.x.
Fukagawa M: Ever-changing concepts of calciphylaxis. Intern Med. 2004, 43 (1): 7-8. 10.2169/internalmedicine.43.7.
Pliquett RU, Schwock J, Paschke R, Achenbach H: Calciphylaxis in chronic, non-dialysis-dependent renal disease. BMC Nephrol. 2003, 4 (1): 8-10.1186/1471-2369-4-8.
Parker RW, Mouton CP, Young DW, Espino DV: Early recognition and treatment of calciphylaxis. South Med J. 2003, 96 (1): 53-55. 10.1097/01.SMJ.0000047841.53171.19.
Somorin AO, Al Harbi A, Subaity Y, Zaman AU: Calciphylaxis: case report and literature review. Afr J Med Med Sci. 2002, 31 (2): 175-178.
Wilmer WA, Magro CM: Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial. 2002, 15 (3): 172-186. 10.1046/j.1525-139X.2002.00052.x.
Hess CT: Calciphylaxis: identification and wound management. Adv Skin Wound Care. 2002, 15 (2): 64-10.1097/00129334-200203000-00006.
Tominaga Y: Uremic calciphylaxis syndrome: calcified uremic artheriolopathy. Intern Med. 2001, 40 (12): 1174-1175.
Trent JT, Kirsner RS: Calciphylaxis: diagnosis and treatment. Adv Skin Wound Care. 2001, 14 (6): 309-312. 10.1097/00129334-200111000-00014.
Selye H: Calciphylaxis. 1962, Chicago, University of Chicago Press
Bryant JH, White WH: A case of calcification of the arteries and obliterative endarteritis associated with hydronephrosis in a child aged six months. Guy's Hospital Rep. 1898, 55: 17-20.
Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, Disney AP: Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis. 1998, 32 (3): 384-391.
Anderson DC, Stewart WK, Pierce DM: Calcifying panniculitis with fat and skin necrosis in a case of uremia with autonomous hyperparathyroidism. Lancet. 1968, 2: 323-325. 10.1016/S0140-6736(68)90531-X.
Llach F: The evolving clinical features of calciphylaxis. Kidney Int Suppl. 2003, 85: S122-124. 10.1046/j.1523-1755.63.s85.29.x.
Cicone JS, Petronis JB, Embert CD, Spector DA: Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 2004, 43 (6): 1104-1108.
Hayden MR, Tyagi SC: Neural redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic neuropathy. Med Sci Monit. 2004, 10 (12): RA291-307.
Miller VM, Rodgers G, Charlesworth JA, Kirkland B, Severson SR, Rasmussen TE, Yagubyan M, Rodgers JC, Cockerill FR, Folk RL, Rzewuska-Lech E, Kumar V, Farell-Baril G, Lieske JC: Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves. Am J Physiol Heart Circ Physiol. 2004, 287 (3): H1115-HI124. 10.1152/ajpheart.00075.2004.
Jelic TM, Malas AM, Groves SS, Jin B, Mellen PF, Osborne G, Roque R, Rosencrance JG, Chang HH: Nanobacteria-caused mitral valve calciphylaxis in a man with diabetic renal failure. South Med J. 2004, 97 (2): 194-198. 10.1097/01.SMJ.0000077067.44311.F0.
Maniscalco BS, Taylor KA: Calcification in coronary artery disease can be reversed by EDTA-tetracycline long-term chemotherapy. Pathophysiology. 2004, 11 (2): 95-101. 10.1016/j.pathophys.2004.06.001.
Ciftcioglu N, McKay DS, Kajander EO: Association between nanobacteria and periodontal disease. Circulation. 2003, 108 (8): e58-59. 10.1161/01.CIR.0000086781.16968.2D.
Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC: Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol. 2000, 20 (8): 1926-1931.
Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004, 292 (4): 490-495. 10.1001/jama.292.4.490.
Mody N, Parhami F, Sarafian TA, Demer LL: Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med. 2001, 31 (4): 509-519. 10.1016/S0891-5849(01)00610-4.
Watts N: Bisphosphonates, statins, osteoporosis, and atherosclerosis. South Med J. 2002, 95 (6): 578-582.
McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR: Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link?. Endocrine. 2004, 23 (1): 1-10. 10.1385/ENDO:23:1:01.
Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, Hofbauer LC, Schaefer JR: Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab. 2004, 89 (8): 3764-3768. 10.1210/jc.2003-032054.
Collin-Osdoby P: Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004, 95 (11): 1046-10574. 10.1161/01.RES.0000149165.99974.12.
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31–2001. A 70-year-old woman with end-stage renal disease and cutaneous ulcers. N Engl J Med. 2001, 345 (15): 1119-1124. 10.1056/NEJMcpc312001.
Wilmer WA, Magro CM: Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial. 2002, 15 (3): 172-186. 10.1046/j.1525-139X.2002.00052.x.
Treit M, Paredes BE, Ruegger S, Brand CU: Typical features of calciphylaxis in a patient with end-stage renal failure, diabetes mellitus and oral anticoagulation. Dermatology. 2000, 200 (4): 356-359. 10.1159/000018410.
Srikureja W, Takahashi PY: 73-year-old woman with painful lower extremity ulcers. Mayo Clin Proc. 2001, 76 (7): 745-748.
Russell R, Brookshire MA, Zekonis M, Moe SM: Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care. Clin Nephrol. 2002, 58 (3): 238-243.
Vassa N, Twardowski ZJ, Campbell J: Hyperbaric oxygen therapy in calciphylaxis-induced skin necrosis in a peritoneal dialysis patient. Am J Kidney Dis. 1994, 23 (6): 878-881.
Pesanti EL: Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am. 2001, 15 (3): 813-832.
Hayden MR: Global risk reduction of reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy. Medical Hypothesis and Research. 2004, 1 (2/3): 171-185.